Xortx Therapeutics Stock Fundamentals
| XRTX Stock | USD 1.21 0.02 1.68% |
XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.
At this time, XORTX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 2.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 996.5 K in 2024. XORTX | Select Account or Indicator |
XORTX Therapeutics Company Shares Owned By Institutions Analysis
XORTX Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current XORTX Therapeutics Shares Owned By Institutions | 6.03 % |
Most of XORTX Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XORTX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 6.03% of XORTX Therapeutics are shares owned by institutions. This is 86.49% lower than that of the Biotechnology sector and 87.31% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 84.62% higher than that of the company.
XORTX Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XORTX Therapeutics's current stock value. Our valuation model uses many indicators to compare XORTX Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XORTX Therapeutics competition to find correlations between indicators driving XORTX Therapeutics's intrinsic value. More Info.XORTX Therapeutics is rated first in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, XORTX Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XORTX Therapeutics' earnings, one of the primary drivers of an investment's value.XORTX Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XORTX Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XORTX Therapeutics could also be used in its relative valuation, which is a method of valuing XORTX Therapeutics by comparing valuation metrics of similar companies.XORTX Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
XORTX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 8.0M | 10.1M | 11.3M | 134.3M | 4.3M | 4.1M | |
| Enterprise Value | 7.8M | 10.1M | 11.2M | 123.9M | 896.6K | 851.8K |
XORTX Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 6.03 % | ||||
| Number Of Shares Shorted | 2.64 K | ||||
| Price To Earning | 170.67 X | ||||
| Price To Book | 1.80 X | ||||
| EBITDA | (4.87 M) | ||||
| Net Income | (2.16 M) | ||||
| Cash And Equivalents | 13.42 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 11.51 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.09 X | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (6.58 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | 0.12 X | ||||
| Price To Earnings To Growth | 9.08 X | ||||
| Target Price | 12.17 | ||||
| Beta | -0.21 | ||||
| Market Capitalization | 4.34 M | ||||
| Total Asset | 5.47 M | ||||
| Retained Earnings | (23.66 M) | ||||
| Working Capital | 3.77 M | ||||
| Current Asset | 341.74 M | ||||
| Current Liabilities | 109.37 M | ||||
| Net Asset | 5.47 M |
About XORTX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 0.90 | 0.80 | |
| Cost Of Revenue | 142 K | 149.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.